4-(Dipropylphosphoryl)aniline | 834894-19-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(Dipropylphosphoryl)aniline
• 英文别名: 4-dipropylphosphorylaniline
• CAS: 834894-19-8
• 化学式: C₁₂H₂₀NOP
• 分子量: 225.271
• InChiKey: LHGFTURRSBCXFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(Dipropylphosphoryl)aniline 、 6-chloro-2-iodo-9-(tetrahydropyran-2-yl)purine 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(4-(Dipropylphosphoryl)phenyl)-2-iodo-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine
  参考文献：
  名称：

  Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors

  摘要：

  Novel N-9-arenethenyl purines, optimized potent dual Src/Abl tyrosine kinase inhibitors, are described. The key structural feature is a trans vinyl linkage at N-9 on the purine core which projects hydrophobic substituents into the selectivity pocket at the rear of the ATP site. Their synthesis was achieved through a Horner-Wadsworth-Emmons reaction of N-9-phosphorylmethylpurines and substituted benzaldehydes or Heck reactions between 9-vinyl purines and aryl halides. Most compounds are potent inhibitors of both Src and Abl kinase, and several possess good oral bioavailability. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.06.042
• 作为产物：
  描述：

  Dipropyl(4-nitrophenyl)phosphine-oxide 在 钯 silica gel 、 methanol-dichloromethane 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以The product was obtained as an orange solid (20.5 g)的产率得到4-(Dipropylphosphoryl)aniline
  参考文献：
  名称：

  Substituted purine derivatives

  摘要：

  本发明涉及通式为以下化合物： 其中Y、RA、RC和R6如定义所述，以及它们的制备和使用。

  公开号：

  US20050065171A1

文献信息

• Unsaturated heterocyclic derivatives
  申请人：ARIAD Pharmaceuticals, Inc.

  公开号：US08071609B2

  公开（公告）日：2011-12-06

  This invention relates to compounds of the general formula: in which Q is an ethynyl or ethenyl moiety; Ring A is an aryl, heteroaryl or heterocyclic ring or ring system; and the remaining variable groups are as defined herein, and to their preparation and use.

  本发明涉及一般式化合物：其中Q是一个乙炔基或乙烯基部分;环A是芳基，杂芳基或杂环环或环系统;其余可变基团如本文所定义，并且涉及它们的制备和使用。
• Unsaturated Heterocyclic Derivatives
  申请人：Wang Yihan

  公开号：US20120178716A1

  公开（公告）日：2012-07-12

  This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

  本发明涉及一般式化合物：其中变量基团如本文所定义，以及它们的制备和使用。
• AMINO PYRIMIDINE ANTICANCER COMPOUNDS
  申请人：APPARI Rama Devi

  公开号：US20110136764A1

  公开（公告）日：2011-06-09

  Compounds of Formula 1, as shown below and defined herein: and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.

  以下为化学式1的化合物，本文中定义：以及其药学上可接受的盐、合成、中间体、制剂和治疗该疾病的方法，包括至少部分由FAK介导的癌症。
• Amino pyrimidine anticancer compounds
  申请人：Appari Rama Devi

  公开号：US08399433B2

  公开（公告）日：2013-03-19

  Compounds of Formula 1, as shown below and defined herein: and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.

  以下式子所示的化合物1及其药学上可接受的盐，合成、中间体、制剂和使用它们治疗疾病的方法，包括至少部分由FAK介导的癌症的治疗方法。
• UNSATURATED HETEROCYCLIC DERIVATIVES
  申请人：ARIAD PHARMACEUTICALS, INC.

  公开号：EP1940843A2

  公开（公告）日：2008-07-09